IP Library › Granted Patent US 12,338,273
Granted Patent B2
US 12,338,273 · App. 17/523,226 · Granted Jun 24, 2025

Single-arm type I and type II receptor fusion proteins and uses thereof

Inventors: Ravindra Kumar (Cambridge, MA); Asya Grinberg (Cambridge, MA); Dianne Sako (Cambridge, MA)
Assignee: Accerelon Pharma Inc.
C07K14/71A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,338,273
App. No.
17/523,226
Granted
Jun 24, 2025
Kind
B2
Abstract

In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used for the treatment or prevention of various TGF-beta associated conditions, including without limitation diseases and disorders associated with, for example, cancer, muscle, bone, fat, red blood cells, metabolism, fibrosis and other tissues that are affected by one or more ligands of the TGF-beta superfamily.

Claims (18)

1. A protein complex comprising a first polypeptide covalently or non-covalently associated with a second polypeptide, wherein:

a. the first polypeptide comprises a TGFβ superfamily type I or type II receptor polypeptide, wherein the TGFβ superfamily type I or type II receptor polypeptide is TGFBRII, and a first constant region from an IgG heavy chain, and wherein the first polypeptide comprises an amino acid sequence that is at least 90% identical to the sequence of any of SEQ ID NOS: 113, 115, 409 and 410; and

b. the second polypeptide comprises a second constant region from an IgG heavy chain, and wherein the second polypeptide does not comprise a TGFβ superfamily type I or type II receptor polypeptide,

and wherein the protein complex exhibits binding to one or more TGF-beta superfamily ligands selected from TGF-β1, TGF-β2, and TGF-β3.

2. The protein complex of claim 1 , wherein the protein complex is a recombinant heterodimer.

3. The protein complex of claim 1 , wherein the second constant region from an IgG heavy chain is an immunoglobulin Fc domain.

4. The protein complex of claim 1 , wherein the first constant region from an IgG heavy chain comprises an amino acid sequence that is at least 90% identical to a sequence selected from any one of SEQ ID NOs: 200-214.

5. The protein complex of claim 1 , wherein the second constant region from an IgG heavy chain comprises an amino acid sequence that is at least 90% identical to a sequence selected from any one of SEQ ID NOs: 200-214.

6. The protein complex of claim 1 , wherein the first polypeptide comprises an amino acid sequence that is at least 95% identical to a sequence selected from any one of SEQ ID NOs: 113, 115, 409, and 410.

7. The protein complex of claim 1 , wherein the second constant region from an IgG heavy chain comprises an amino acid sequence comprises an amino acid sequence that is at least 95% identical to a sequence selected from any one of SEQ ID NOs: 139 and 426.

8. The protein complex of claim 1 , wherein the first polypeptide and/or second polypeptide comprises one or more modified amino acid residues selected from: a glycosylated amino acid, a PEGylated amino acid, a farnesylated amino acid, an acetylated amino acid, a biotinylated amino acid, and an amino acid conjugated to a lipid moiety.

9. The protein complex of claim 1 , wherein the first polypeptide and/or second polypeptide is glycosylated and has a glycosylation pattern obtainable from expression of the type I receptor polypeptide in a CHO cell.

10. The protein complex of claim 1 , wherein the protein complex has one or more of the following characteristics: i) binds to the TGF-beta superfamily ligand with a K D of less than or equal to 10-7; and ii) inhibits TGF-beta superfamily type I and/or type II receptor-mediated signaling transduction in a cell.

11. A pharmaceutical preparation comprising the protein complex of claim 1 and a pharmaceutically acceptable carrier.

12. The pharmaceutical preparation of claim 11 , wherein the preparation is adapted for parenteral administration.

13. The protein complex of claim 1 , wherein the first polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 115, 409, and 410.

14. The protein complex of claim 1 , wherein the second constant region from an IgG heavy chain comprises the amino acid sequence of SEQ ID NO: 139 or 426.

15. The recombinant protein complex of claim 1 , wherein the protein complex exhibits weak or substantially no binding to BMP9 and/or BMP10.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2022
From: KUMAR, RAVINDRA; GRINBERG, ASYA; SAKO, DIANNE
To: ACCELERON PHARMA INC.
Reel/Frame 060464/0572 →
Continuity (5)
Division 16423593 · May 28, 2019
Division 15092600 · Apr 6, 2016
Provisional Application 62259422 · Nov 24, 2015
Provisional Application 62143579 · Apr 6, 2015
Related Publication 20220315642A1 · Oct 6, 2022
References Cited (147)
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5932448A · Tso et al. · 1999 [cited by applicant]
US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]
US 7612041B2 · Knopf et al. · 2009 [cited by applicant]
US 7709605B2 · Knopf et al. · 2010 [cited by applicant]
US 7820620B2 · Vale et al. · 2010 [cited by applicant]
US 7842663B2 · Knopf et al. · 2010 [cited by applicant]
US 8252900B2 · Knopf et al. · 2012 [cited by applicant]
US 8338377B2 · Seehra · 2012 [cited by applicant]
US 8361957B2 · Seehra et al. · 2013 [cited by applicant]
US 8410043B2 · Sun et al. · 2013 [cited by applicant]
US 8592562B2 · Kannan et al. · 2013 [cited by applicant]
US 8703927B2 · Seehra et al. · 2014 [cited by applicant]
US 8734760B2 · O'Connor-McCourt et al. · 2014 [cited by applicant]
US 9181533B2 · Seehra et al. · 2015 [cited by applicant]
US 9611306B2 · Hinck et al. · 2017 [cited by applicant]
US 9809638B2 · Sun et al. · 2017 [cited by applicant]
US 9975934B2 · Kumar et al. · 2018 [cited by applicant]
US 20100168020A1 · Sun et al. · 2010 [cited by applicant]
US 20100330657A1 · Miyazono et al. · 2010 [cited by applicant]
US 20110236309A1 · O'Connor-McCourt et al. · 2011 [cited by applicant]
US 20120247863A1 · Lamoine et al. · 2012 [cited by applicant]
US 20120302737A1 · Christensen et al. · 2012 [cited by applicant]
US 20160289292A1 · Kumar et al. · 2016 [cited by applicant]
US 20160297867A1 · Kumar et al. · 2016 [cited by applicant]
US 20160298093A1 · Kumar et al. · 2016 [cited by applicant]
US 20170306027A1 · Knopf et al. · 2017 [cited by applicant]
US 20180008672A1 · Chalothorn et al. · 2018 [cited by applicant]
US 20180072791A1 · Sun et al. · 2018 [cited by applicant]
US 20180111991A1 · Miller et al. · 2018 [cited by applicant]
US 20180148491A1 · Han et al. · 2018 [cited by applicant]
US 20180163187A1 · Kumar et al. · 2018 [cited by applicant]
US 20190100570A1 · Kumar et al. · 2019 [cited by applicant]
EP 3101029A1 · 2016 [cited by applicant]
JP 2010518009A · 2010 [cited by applicant]
JP 2011526626A · 2011 [cited by applicant]
JP 2012529294A · 2012 [cited by applicant]
JP 2013510090A · 2013 [cited by applicant]
WO 1984001106A1 · 1984 [cited by applicant]
WO 1993011162A1 · 1993 [cited by applicant]
WO 2000043781A2 · 2000 [cited by applicant]
WO 2004039948A2 · 2004 [cited by applicant]
WO 2005028433A2 · 2005 [cited by applicant]
WO 2005028517A2 · 2005 [cited by applicant]
WO 2005047336A1 · 2005 [cited by applicant]
WO 2006012627A2 · 2006 [cited by applicant]
WO 2007147901A1 · 2007 [cited by applicant]
WO 2008057461A2 · 2008 [cited by applicant]
WO 2008097541A2 · 2008 [cited by applicant]
WO 2009089004A1 · 2009 [cited by applicant]
WO 2009134428A2 · 2009 [cited by applicant]
WO 2009158033A2 · 2009 [cited by applicant]
WO 2010062383A2 · 2010 [cited by applicant]
WO 2010151426A1 · 2010 [cited by applicant]
WO 2011034605A2 · 2011 [cited by applicant]
WO 2011045497A1 · 2011 [cited by applicant]
WO 2011056497A1 · 2011 [cited by applicant]
WO 2011056896A1 · 2011 [cited by applicant]
WO 2011117329A1 · 2011 [cited by applicant]
WO 2013000234A1 · 2013 [cited by applicant]
WO 2015027082A1 · 2015 [cited by applicant]
WO 2016205370A1 · 2016 [cited by applicant]
WO 2017037634A1 · 2017 [cited by applicant]
WO 2018009624A1 · 2018 [cited by applicant]
WO 2018075747A1 · 2018 [cited by applicant]
Allendorph, George P. et al., Structure of the ternary signaling complex of a TGF-β superfamily member, PNAS, 2006, 7643-7648, 103(20). [cited by applicant]
Andersson, Olov et al., Growth differentiation factor 11 signals through the transforming growth factor-β receptor ALK5 to regionalize the anterior-posterior axis, EMBO Reports, 2006, 831-837, 7(8). [cited by applicant]
Andersson, Olov et al., Growth/differentiation factor 3 signals through ALK7 and regulates accumulation of adipose tissue and diet-induced obesity, PNAS, 2008, 7252-7256, 105(2). [cited by applicant]
Ashmore, C.R. et al., Comparative aspects of muscle fiber types in fetuses of the normal and “double-muscled” cattle, Growth, 1974, 501-506, 38(4). [cited by applicant]
Attisano, Liiana et al., Novel Activin Receptors: Distinct Genes and Alternative mRNA Splicing Generate a Repertoire of Serine/Threonine Kinase Receptors, Cell, 1992, 97-108, 68. [cited by applicant]
Berasi, Stephen P. et al., Divergent activities of osteogenic BMP2, and tenogenic BMP12 and BMP13 Independent of receptor binding affinities, Growth Factors, 2011, 128-139, 29:4. [cited by applicant]
Bogdanovich, Sasha et al., Functional improvement of dystrophic muscle by myostatin blockade, Nature, 2002, 418-421, 420. [cited by applicant]
Brown, Peter D. et al., Physicochemical Activation of Recombinant Latent Transforming Growth Factor-beta's 1, 2, and 3, Growth Factors, 1990, 35-43, 3:1. [cited by applicant]
Cheng, Li et al., Transforming Growth Factor-β1 (TGF-β1) Induces Mouse Precartilaginous Stem Cell Proliferation through TGF-β Receptor II (TGFRII)-Akt-β-Catenin Signaling, Int. J. Mol. Sci., 2014, 12665-12676, 14. [cited by applicant]
Chiu, Chi-Sung et al., Increased Muscle Force Production and Bone Mineral Density in ActRIIB-Fc-Treated Mature Rodents, J Gerontol A Biol Sci Med Sci, 2013, 1181-1192, 68(10). [cited by applicant]
Clouthier, David E. et al., Hepatic Fibrosis, Glomerulosclerosis, and a Lipodystrophy-like Syndrome in PEPCK-TGF-β1 Transgenic Mice, J. Clin. Invest., 1997, 2697-2713, 100. [cited by applicant]
Cunha, Sara I. et al., ALK1 as an emerging target for antiangiogenic therapy of cancer, Blood, 2011, 6999-7006, 117(26). [cited by applicant]
Davis, Jonathan H. et al., SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies, rot… [cited by applicant]
De Silva, Tanya et al., Nodal promotes glioblastoma cell growth, Frontiers in Endocrinology, 2012, 1-6, 3:59. [cited by applicant]
Del Re, Elisabetta et al., Reconstitution and Analysis of Soluble Inhibin and Activin Receptor Complexes in a Cell-free System, The Journal of Biological Chemistry, 2004, 53126-53135, vol. 279, No. 51. [cited by applicant]
Demirhan, O. et al., A homozygous BMPR1B mutation causes a new subtype of acromesomelic chondrodysplasia with genital anomalies, J Med Genet, 2005, 314-317, 42. [cited by applicant]
Depaolo, Louis V. et al., Follistatin and Activin: A Potential Intrinsic Regulatory System within Diverse Tissues, Proceedings of the Society for Experimental Biology and Medicine, 1991, 500-512, 198:1. [cited by applicant]
Di Clemente, Nathalie et al., Processing of Anti-Mullerian Hormone Regulates Receptor Activation by a Mechanism Distinct from TGF-β, Mol Endocrinol, 2010, 2193-2206, 24(11). [cited by applicant]
Dyson, Steven et al., Activin signalling has a necessary function in Xenopus early development, Current Biology, 1997, 81-84, 7. [cited by applicant]
Fukuda, Toru et al., Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva, The Journal of Biological Chemistry, 2009, 714… [cited by applicant]
Gamer, Laura W. et al., A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer in Xenopus Embryos, Developmental Biology, 1999, 222-232, 208. [cited by applicant]
Gamer, Laura W. et al., Gdf11 Is a Negative Regulator of Chondrogenesis and Myogenesis in the Developing Chick Limb, Developmental Biology, 2001, 407-420, 229. [cited by applicant]
Gibco, Recombinant Human Activin A Receptor, Type 1B (ACVR1B), Life Technologies Corporation, 2011, 1-2, Manual. [cited by applicant]
Gonzalez-Cadavid, Nestor F. et al., Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting, Proc. Natl. Acad. Sci. USA, 1998, 14938-14943, 95. [cited by applicant]
Goumans, Marie-Jose et al., Activin Receptor-like Kinase (ALK)1 Is an Antagonistic Mediator of Lateral TGFβ/ALK5 Signaling, Molecular Cell, 2003, 817-828, 12. [cited by applicant]
Greenwald, Jason et al., Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase, Nature Structural Biology, 1999, 18-22, 6. [cited by applicant]
Grobet, Luc et al., A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle, nature genetics, 1997, 71-74, 17. [cited by applicant]
Gunasekaran, Kannan et al., Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects, The Journal of Biological Chemistry, 2010, 19637-19646, 285(25). [cited by applicant]
Hilden, Kristiina et al., Expression of Type II Activin Receptor Genes During Differentiation of Human K562 Cells and cDNA Cloning of the Human Type IIB Activin Receptor, Blood, 1994, 2163-2170, 83(8). [cited by applicant]
Hinck, Andrew P., Structural studies of the TGF-βs and their receptors—insights into evolution of the TGF-β superfamily, FEBS Letters, 2012, 1860-1870, 586. [cited by applicant]
Huang, Chichi, Receptor-Fc fusion therapeutics, traps, and Mimetibody technology, Current Opinion in Biotechnology, 2009, 692-699, 20. [cited by applicant]
Kabat, Heavy Constant Chains Ch3 Region, Sequences of Proteins of Immunological Interest, 1991, 688-696, 91 (3242). [cited by applicant]
Kambadur, Ravi et al., Mutations in myostatin (GDF8) in Double-Muscled Belgian Blue and Piedmontese Cattle, Genome Research, 1997, 910-915, 7. [cited by applicant]
Kamiya, Nobuhiro et al., BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway, Development, 2008, 3801-3811, 135. [cited by applicant]
Kamiya, Nobuhiro et al., Disruption of BMP Signaling in Osteoblasts Through Type IA Receptor (BMPRIA) Increases Bone Mass, J Bone Miner Res, 2008, 2007-2017, 23(12). [cited by applicant]
Kaplan, Frederick S. et al., Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis, Ann. N.Y. Acad. Sci., 2011, 5-10, 1237. [cited by applicant]
Kemaladewi, Dwi U. et al., Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor, Molecular Therapy—Nucleic Acids, 2014, 1-8, 3, e156. [cited by applicant]
Klein, Christian et al., Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies, mAbs, 2012, 653-663, 4(6). [cited by applicant]
Komesli, Sylviane et al., Chimeric extracellular domain of type II transforming growth factor (TGF)-3 receptor fused to the Fc region of human immunoglobulin as a TGF-β antagonist, Eur. J. Biochem., 1998, 505-513, 254. [cited by applicant]
Koncarevic, A. et al., A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health, Endocrinology, 2010, 4289-4300, 151(1). [cited by applicant]
Konrad, Lutz et al., Alternative splicing of TGF-betas and their high-affinity receptors TβRI, TβRII and TβRIII (betaglycan) reveal new variants in human prostatic cells, BMC Genomics, 2007, 1-13, 8:318. [cited by applicant]
Kubiczkova, Lenka et al., TGF-β—an excellent servant but a bad master, Journal of Translational Medicine, 2012, 1-24, 10:183. [cited by applicant]
Larsson, Jonas et al., Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice, The EMBO Journal, 2001, 1663-1673, 20(7). [cited by applicant]
Lavery, Karen et al., BMP-2/4 and BMP-6/7 Differentially Utilize Cell Surface Receptors to Induce Osteoblastic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells, The Journal of Biological Chemistry, 20… [cited by applicant]
Li, Ming O. et al., Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms, Immunity, 2006, 455-471, 25. [cited by applicant]
Lin, S Jack et al., The structural basis of TGF-β, bone morphogenetic protein, and activin ligand binding, Reproduction, 2006, 179-190, 132. [cited by applicant]
Maci'as-Silva, Marina et al., Specific Activation of Smad1 Signaling Pathways by the BMP7 Type I Receptor, ALK2, The Journal of Biological Chemistry, 1998, 25628-25636, vol. 273, No. 40. [cited by applicant]
Maeshima, Akito et al., Follistatin, an Activin Antagonist, Ameliorates Renal Interstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction, BioMed Research International, 2014, 1-10, Article ID 376191. [cited by applicant]
Massagué, Joan, How Cells Read TGF-β Signals, Nature Reviews Molecular Cell Biology, 2000, 169-178, 1 (3). [cited by applicant]
McPherron, Alexandra C. et al., Double muscling in cattle due to mutations in the myostatin gene, Proc. Natl. Acad. Sci. USA, 1997, 12457-12461, 94. [cited by applicant]
McPherron, Alexandra C. et al., Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11, nature genetics, 1999, 260-264, 22. [cited by applicant]
McPherron, Alexandra C. et al., Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member, Nature, 1997, 83-90, 387. [cited by applicant]
Merchant, A. Margaret et al., An efficient route to human bispecific IgG, Nature Biotechnology, 1998, 677-681, 16. [cited by applicant]
Mishina, Yuji et al., Multiple Roles for Activin-Like Kinase-2 Signaling during Mouse Embryogenesis, Developmental Biology, 1999, 314-326, 213. [cited by applicant]
Mitchell, Dianne et al., ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth, Mol Cancer Ther, 2010, 379-388, 9(2). [cited by applicant]
Miyazono, Kohei et al., Latent High Molecular Weight Complex of Transforming Growth Factor β1, The Journal of Biological Chemistry, 1988, 6407-6415, 263(13). [cited by applicant]
Nakashima, Misako et al., Expression of growth/differentiation factor 11, a new member of the BMP/TGFβ superfamily during mouse embryogenesis, Mechanisms of Development, 1999, 185-189, 80. [cited by applicant]
Pack, Peter et al., Improved bivalent miniantbodies, with identical avidity as whole antibodies, produced by high cell density fermentation of [cited by applicant]
Pack, Peter et al., Miniantibodies: Use of Amphipathic Helices to Produce Functional, Flexibly Linked Dimeric Fv Fragments with High Avidity in [cited by applicant]
Pistilli, Emidio E. et al., Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy, The American Journal of Pathology, 2011, 1287-1297, vol. 178… [cited by applicant]
Qin, Tai et al., A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands, Oncotarget, 2016, 86087-86102, 7(52). [cited by applicant]
Rider, Christopher C. et al., Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists, Biochem. J., 2010, 1-12 + Supplementary Online Data 3 pp. 429. [cited by applicant]
Ridgway, John B.B. et al., ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization, Protein Engineering, 1996, 617-621, 9(7). [cited by applicant]
Roberts, Heather J. et al., Identification of Novel Isoforms of Activin Receptor-Like Kinase 7 (ALK7) Generated by Alternative Splicing and Expression of ALK7 and Its Ligand, Nodal, in Human Placenta, Biology of Reprodu… [cited by applicant]
Rosenzweig, Bradley L. et al., Cloning and characterization of a human type II receptor for bone morphogenetic proteins, Proc. Natl. Acad. Sci. USA, 1995, 7632-7636, 92. [cited by applicant]
Sako, Dianne et al., Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB, Journal of Biological Chemistry, 2010, 21037-21048, 285(27). [cited by applicant]
Schuelke, Markus et al., Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child, N Engl J Med, 2004, 2682-2688, 350. [cited by applicant]
Spiess, Christoph et al., Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies, Nature Biotechnology, 2013, 753-758, 31(8). [cited by applicant]
Supplementary Partial European Search Report for EP16777227 dated Sep. 19, 2018, 5 pages. [cited by applicant]
Swatland, H. J. et al., Fetal development of the double muscled condition in cattle, Journal of Animal Science, 1974, 752-757, 38(4). [cited by applicant]
Ten Dijke, Peter, et al., Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity, Oncogene, 1993, 2879-2887, 8(10). [cited by applicant]
Thompson, Thomas B. et al., Structures of an ActRIIB: activin A complex reveal a novel binding mode for TGF-β ligand: receptor interactions, The EMBO Journal, 2003, 1555-1566, 22(7). [cited by applicant]
Tsuchida, Kunihiro et al., Signal Transduction Pathway through Activin Receptors as a Therapeutic Target of Musculoskeletal Diseases and Cancer, Endocrine Journal, 2008, 11-21, 55(1). [cited by applicant]
Wakefield, Lalage M. et al., Latent Transforming Growth Factor-β from Human Platelets, The Journal of Biological Chemistry, 1988, 7646-7654, 263(16). [cited by applicant]
Weiss, Alexander et al., The TGFbeta Superfamily Signaling Pathway, Developmental Biology, 2013, 47-63, 2. [cited by applicant]
Woodruff, Teresa K., Regulation of Cellular and System Function by Activin, Biochemical Pharmacology, 1998, 953-963, 55. [cited by applicant]
Wranik, Bernd J. et al., LUZ-Y, a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific Antibodies, The Journal of Biological Chemistry, 2012, 43331-43339, vol. 287, No. 52. [cited by applicant]
Wu, Hsiao-Huei et al., Autoregulation of Neurogenesis by GDF11, Neuron, 2003, 197-207, 37. [cited by applicant]
Yi, Soyun E. et al., The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb, Development, 2000, 621-630, 127. [cited by applicant]
Zec, Ivana et al., Anti-Müllerian hormone: A unique biochemical marker of gonadal development and fertility in humans, Biochemia Medica, 2011, 219-230, 21(3). [cited by applicant]
Zimmers, Teresa A. et al., Induction of Cachexia in Mice by Systemically Administered Myostatin, Science, 2002, 1486-1488, 296. [cited by applicant]
Zwaagstra, John C. et al., Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps, Mol Cancer Ther, 2012, 1477-1487, 11(7). [cited by applicant]